Search Within

Issam S. Hamadeh

Formats
  1. Meeting Abstract (16)
  2. Journal Article (4)
  3. Review (2)
Groups
  1. Clinical Pharmacy Specialists (22)
  2. Hematologic Malignancies, Division of (20)
  3. Center for Hematologic Malignancies (19)
  4. Department of Medicine (19)
  5. Myeloma (19)
  6. Bone Marrow Transplant (18)

More Groups

People
  1. Carlyn Rose Tan (19)
  2. Sham Mailankody (19)
  3. Alexander Lesokhin (18)
  4. David Chung (18)
  5. Hani Hassoun (18)
  6. Heather Landau (18)

More People

Years
  1. 2025 (1)
  2. 2024 (14)
  3. 2023 (5)
  4. 2022 (2)
Publications
  1. Blood (9)
  2. Clinical Lymphoma, Myeloma and Leukemia (7)
  3. Blood Advances (3)
  4. Annals of Hematology (1)
  5. Cancer Management and Research (1)
  6. Frontiers in Oncology (1)
Publishers
  1. American Society of Hematology (12)
  2. Elsevier Inc. (7)
  3. Dove Medical Press Ltd (1)
  4. Frontiers Media S.A. (1)
  5. Springer (1)

Results (22)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Perspectives on talquetamab and its utility in the treatment of multiple myeloma: Safety, efficacy and place in therapy
    Review

    Miller, K. C.; Hamadeh, I.; Tan, C. R.
    Cancer Management and Research (2025)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B. A.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save